大家在查： hermetically sealed bargain hunter SiCortex 高沟 lures 周渝民穆塔基天朝 fundamentallysound 一千二百万

Rituximab

网络利妥昔单抗；美罗华；莫须瘤

Rituximab

网络释义

Rituximab

利妥昔单抗

利妥昔单抗（Rituximab）：商品名Rituxan，年销售额72.85亿美元曲妥珠单抗（Trastuzumab）：商品名Herceptin，年销售额6…

美罗华

罗氏美罗华（Rituximab）有益于特发性膜性肾病临床治疗关注我们特别专题分享到：关注生物制药、创投、项目技术的新鲜 …

莫须瘤

单株抗体莫须瘤 (Rituximab) 的发明让滤泡型淋巴瘤的治疗有了突飞猛进的进展 . Hiddemann 等人的研究显示 , 经 CHOP 治疗 …

单克隆抗体

41.1.7 抗-CD20单克隆抗体（Rituximab）(美罗华) Rituximab 375mg/m2 i.v.

单克隆抗体美罗华

在较早期的研究中用抗CD20的单克隆抗体美罗华（rituximab）治疗复发、低度恶性的NHL病人取得了可喜的成果，在一个有16…

单克隆抗体利妥昔

近年来，抗CD20单克隆抗体利妥昔(Rituximab)的应用进一步提高了DLBCL的临床疗效，但仍有30-40％的患者对治疗无效或治 …

利托昔

　　利托昔（Rituximab）是1997年FDA批准用于治疗B淋巴细胞NHL的抗CD20嵌合型单克隆抗体，是由鼠抗CD20的可变区Fab和 …

例句：

There was no increase in infections or neutropenia with rituximab.

感染和中性粒细胞减少症都没有增加。

Conclusion : Rituximab is a fine and phamacoeconomic choice for non-Hodgkin's lymphoma with satisfactory efficacy and safety .

结论：利妥昔单抗具有较好的疗效和安全性，也是治疗非霍奇金淋巴瘤较经济的方法。

Addition of GM-CSF did not impair tolerance to rituximab , and adverse events were rare and mild .

添加 GM-CSF 不减弱美罗华的耐受性，不良反应很少，并且很轻。

It is possible to achieve selective depletion of B lymphocytes with rituximab, an anti-CD20 monoclonal antibody .

用抗 CD20 的单克隆抗体利妥昔单抗能够做到选择性的消耗 B 淋巴细胞。

Patients get rituximab through infusion into a vein (IV) at the oncologist 's office or clinic .

患者可在肿瘤专家的办公室或门诊接受静脉注入美罗华。

The improved efficacy over rituximab monotherapy may be due to increases seen in monocyte , granulocyte, and dendritic cell populations .

与单用美罗华相比，疗效的增加可以通过单核细胞、粒细胞、树突状细胞等群系的增长显现。

Some experts are already questioning the need for the lymphoma vaccine when a drug , rituximab, exists to control the disease.

一些专家已在质疑，当已经有一种叫美罗华（rituximab ）的药能控制淋巴瘤时，是否还要去研究淋巴瘤疫苗。

We observed an aggravation of concomitant cutaneous Kaposi sarcoma , and hypothesize that rituximab could have exacerbated it.

我们观察到的恶化伴随皮肤卡波西氏肉瘤，并推测这种美罗华可能加剧。

Rituximab in combination with chemotherapy resulted in durable remission in a heavily pretreated subgroup.

利妥昔单抗联合化疗可使既往多次化疗的患者获得持续缓解。

Objective To evaluate the efficacy and toxicity of combination of Rituximab and CHOP regimen in diffuse large B -cell lymphoma (DLBCL).

目的观察利妥昔单抗联合 CHOP 方案（R-CHOP ）治疗初治弥漫大 B 细胞型淋巴瘤的疗效以及毒副反应。

Rituximab may be effective in controlling MCD in a subset of patients .

美罗华可有效地控制麦当劳中的一个子集的患者。

Rituximab specifically recognizes and attaches to a protein called CD20 that is found on the surface of some lymphocytes .

美罗华特异的识别和附着于在一些淋巴细胞表面可以找到蛋白 CD20 。

This study was to investigate the efficacy and safety of rituximab-containing regimens for patients with indolent B-cell lymphoma in China .

本研究目的是观察含美罗华方案治疗我国惰性淋巴瘤的疗效和安全性。

The adverse reaction was observed in 11 out of 100 patients during intravenous infusion of rituximab .

100 例患者中共有 11 例因静脉输注利妥昔单抗而发生输液不良反应。

No long-term toxicity potentially due to rituximab was observed .

未见利妥昔单抗的长期潜在毒性。

Indeed , Dr Huff and Dr Matsui could see stem cells coated with the antibodies alive and well in their samples.

事实上，博士 Huff 和博士 Matsui 证实了干细胞能在 rituximab 包裹的条件下很好的存活。

Rituximab may be effective for the treatment of CD20-positive MM .

美罗华可有效地用于治疗抗 CD20 阳性毫米。

If this coats the myeloma stem cells in the way that rituximab does, the radiation should kill them .

如果这种抗体能像 rituximab 那样包裹住干细胞，那么标记的放射性将会杀死它们。

Results At 1 year , the mean AUC for the level of C peptide was significantly higher in the rituximab group than in the placebo group .

结果：一年以后，利妥昔单抗组 C 肽水平的平均曲线下面积明显高于安慰机组。

Methods 6 elderly patients with B-cell Non-Hodgkin's Lymphoma were treated with Rituximab combined with CTNP regiment in our department.

方法 6 例经病理证实为 B 细胞非霍奇金淋巴瘤高龄患者采用美罗华联合 CTNP 方案化疗。

CD19+ B lymphocytes were depleted in patients in the rituximab group , but levels increased to 69% of baseline values at 12 months .

CD19 阳性的 B 淋巴细胞在利妥昔单抗组里被耗尽，但是在低 12个月的时候又回复到基线值的 69%。

More patients in the rituximab group than in the placebo group had adverse events , mostly grade 1 or grade 2 , after the first infusion .

更多的利妥昔单抗组的患者在第一次注射后发生不良反应，大多数都是 1 或 2 级的。

A study of rituximab combined with DICE regimen for treatment of the relapsed or refractory aggressive B-cell Lymphoma

美罗华联合 DICE 方案治疗复发和难治性侵袭性 B 细胞淋巴瘤

Rituximab

Rituximab

利妥昔单抗

美罗华

莫须瘤

单克隆抗体

单克隆抗体美罗华

单克隆抗体利妥昔

利托昔

热词推荐

大家在看